What is the difference between ms contin and percocet

Eur J Pain. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

Clin Drug Investig. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. Google Scholar. Clinical application of opioid equianalgesic data.

Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Palliative pain management: when both pain and suffering hurt. J Palliat Care. Substance abuse in cancer pain. Curr Pain Headache Rep. A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain.

A comprehensive review of opioid-induced hyperalgesia. Peripherally acting opioids and clinical implications for pain control. Higgins J, et al. Quantifying heterogeneity in a meta-analysis. Stat Med. Measuring inconsistency in meta-analyses. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients EXHEAL: a phase III study of EXtended-release HydromorphonE for cAncer pain reLief.

J Pain Res. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Ann Oncol. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J Pain Symptom Manag. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.

J Pain. Comparison of the tolerability profile of controlled-release oral morphine and oxycodone for Cancer pain treatment. An open-label randomized controlled trial. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.

Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the dark Agouti rat.

J Pharmacol Exp Ther. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Anti-nociception by spinal and systemic oxycodone: why does the route make a difference? Riviere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand J Gastroenterol.

A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. Kalso E. How different is oxycodone from morphine? Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte trafficking. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and mu 3 opiate receptor-dependent mechanism.

J Neuroimmunol. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Lethality of morphine in mice infected with toxoplasma gondii. Effects of morphine dependence on the pathogenesis of swine herpesvirus infection. J Infect Dis. Immunomodulatory effects of in vitro exposure to morphine and its metabolites. Morphine-6b-glucuronide induces potent immunomodulation.

Int Immunopharmacol. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Genetics and variability in opioid response. Oxymorphone revisited. Semin Anesth. Multiple loci modulate opioid therapy response for cancer pain.

Clin Cancer Res. Analgesia and central side-effects: two separate dimensions of morphine response. Br J Clin Pharmacol. Opioid genetics: the key to personalized pain control? Clin Genet. Evolving knowledge of opioid genetics in cancer pain. Clin Oncol R Coll Radiol. Heiskanen T, Kalso E.

Controlled-release oxycodone and morphine in cancer related pain. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study.

Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. Download references. The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

You can also search for this author in PubMed Google Scholar. Kai-Kai Guo made substantial contributions to conception and design of the study; Cheng-Qi Deng, Gui-Jun Lu and Guo-Li Zhao searched literature, extracted data from the collected literature and analyzed the data; Kai-Kai Guo wrote the manuscript; Gui-Jun Lu revised the manuscript; All authors approved the final version of the manuscript.

Correspondence to Gui-Jun Lu. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reprints and Permissions. They are different versions of the same drug. OxyContin and immediate-release oxycodone belong to a drug class called opioids.

A class of drugs is a group of medications that work in a similar way and are often used to treat similar conditions. Immediate-release oxycodone and OxyContin both bind to receptors in your brain and spinal cord.

When they do this, they block pain signals and stop pain. Immediate-release oxycodone is used to treat moderate to severe pain, such as from surgery or an injury. OxyContin is usually reserved for longer-lasting pain from the late stages of a long-term disease, usually cancer.

Doctors may sometimes add immediate-release oxycodone to treatment with OxyContin during brief moments when the pain becomes severe. Both immediate-release oxycodone and OxyContin are powerful pain relievers. They both have been shown to be highly effective at treating pain. Oxycodone immediate-release tablets are available as generic drugs.

They usually cost less than OxyContin. Your insurance plan may also prefer generic oxycodone over OxyContin. This means they may cover only one of the drugs or only generic forms.

You should call your insurance company to ask if one drug is preferred over the other. You should also call your pharmacy to see if they keep these drugs in stock. Not all pharmacies carry these drugs. The side effects of oxycodone and OxyContin are very similar. This is because they contain the same active ingredient. The most common side effects of these drugs include:.

Learn more: Detailed drug information for oxycodone ». An interaction is when a substance changes the way a drug works. This can be harmful or prevent the drug from working well. Do not drink alcohol while taking immediate-release oxycodone or OxyContin. This combination can be deadly. Immediate-release oxycodone and OxyContin can make these conditions worse.

If you are breastfeeding, do not take either of these drugs. Both of these drugs can pass through breast milk and harm your child. The occurrence rates of adverse reactions were Conclusion: Morphine, MS contin and oxycodone give similar pain relief and adverse reaction rates but of all, morphine is the preferred drug for the treatment of cancer pain from the perspective of pharmacoeconomics.

Abstract Objective: To analyze cost-effectiveness of morphine, MS contin and oxycodone in the treatment of cancer pain, providing guidance for rational drug use in the clinic.